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The COVID-19 pandemic is moving at a rapid rate, both in global
transmission and in our knowledge about the disease. Health autho-
rities across the world are scrambling to delineate best practices for
everything from appropriate personal protective equipment, to anti-
viral therapy, and ARDS management strategies. It that context, Nicola
et al. present an excellent consolidation of what we currently know
about the disease and what evidence we have to support particular
management approaches [1]. They offer an evidence-based summary of
the known epidemiology of the disease and the preventative measures
being used to slow transmission, including social distancing, school
closures, and quarantining. They also review the current treatment
recommendations for those with severe disease, including a brief dis-
cussion of experimental treatments.
While this is a valuable review, several aspects of COVID-19 man-
agement are already in flux. Despite the authors' recommendation
against routine mask use, many governments, including the United
States, are now recommending widespread public use of cloth masks to
help decrease transmission, with some emerging evidence that masks
may have efficacy with limited risks [2]. Also, in contrast to the au-
thors’ argument, the use of chloroquine-based medications, promoted
through open-label, non-randomized data from France, has become a
controversial treatment with disagreement about the potential benefits
and rising concerns about the cardiac toxicity, among other serious side
effects [3]. Other treatments such as convalescent plasma transfusion
and remdesivir are also gaining substantial interest and may prove to be
effective therapies, but more randomized data is needed [4]. These
recent, and relatively dramatic changes in consensus about appropriate
treatments for COVID-19, imply that we should proceed very cautiously
as we establish a standard set of prevention and treatment guidelines.
As many countries emerge from the peak of transmission, it is be-
coming increasingly clear that public health officials will need to de-
termine the role for antibody testing and vaccinations. Recent evidence
suggests asymptomatic prevalence may be as high as 15% in specific
populations, potentially affecting strategies for screening and tracing in
some regions [5]. Antibody testing is still not widely available, making
it difficult to honestly assess the breadth of the pandemic and the po-
tential for herd immunity. Vaccinations will also be a vital aspect of any
future population-level interventions, although the timeline of their
availability remains unclear. These continued uncertainties, about both
the epidemiology of COVID-19 and the readiness of vital public health
tools such as testing and vaccinations, requires flexibility in the inter-
pretation of evidence-based standards and caution is imperative. Un-
fortunately, evidence is lagging behind the speed of the pandemic, so
we must vigilant in regularly reassessing our current strategies.
Provenance and peer review
Invited Commentary, internally reviewed.
References
[1] M. Nicola, N. O'Neill, C. Sohrabi, M. Khan, R. Agha, Evidence based management
guideline for the COVID-19 pandemic - review article, Int. J. Surg. (2020).
[2] T. Greenhalgh, M.B. Schmid, T. Czypionka, D. Bassler, L. Gruer, Face masks for the
public during the covid-19 crisis, BMJ (2020) 369.
[3] S. Jaffe, Regulators split on antimalarials for COVID-19, Lancet 395 (10231) (2020)
1179.
[4] A. Casadevall, L. Pirofski, The convalescent sera option for containing COVID-19, J.
Clin. Invest. 130 (4) (2020).
[5] D. Sutton, K. Fuchs, M. D'Alton, D. Goffman, Universal screening for SARS-CoV-2 in
women admitted for delivery, NEJM (2020).
Jared Gallaher, Anthony Charles∗
Department of Surgery, University of North Carolina at Chapel Hill, United
States
E-mail address: anthony_charles@med.unc.edu (A. Charles).
DOI of original article: https://doi.org/10.1016/j.ijsu.2020.04.001
∗ Corresponding author. UNC School of Medicine, 4008 Burnett Womack Building, CB, 7228, United States.
https://doi.org/10.1016/j.ijsu.2020.04.030
Received 15 April 2020; Accepted 15 April 2020
Available online 21 April 2020
T
